John Mendlein is Director at FATE THERAPEUTICS INC (FATE). They have made 9 open-market trades across 2 companies since 2013, most recently 2023-01-19.
CIK 0001238362
7 open-market purchases totalling $2.0M since 2013, against 2 sales. Across 7 scored buys the stock is up 12.3% at ninety days, and 7.4 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 57% | 57% |
| Avg Move | +9.3% | +21.9% | +12.3% |
| Alpha | +8.3% | +19.3% | +7.4% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FATE | BUY | 2023-01-11 | 2023-01-13 | $5.60 | $1.4M | -7.5% | +11.5% | +8.2% |
| FATE | SELL | 2022-06-03 | 2022-06-06 | $22.79 | $31K | -10.4% | +32.5% | +17.1% |
| FATE | SELL | 2022-03-10 | 2022-03-11 | $35.02 | $2.2M | +11.3% | +7.9% | -29.3% |
| LIFE | BUY | 2018-12-20 | 2018-12-26 | $0.42 | $102K | +21.8% | +24.3% | +16.9% |
| LIFE | BUY | 2017-08-31 | 2017-09-05 | $2.65 | $200K | +27.6% | +96.6% | +34.5% |
| LIFE | BUY | 2017-04-24 | 2017-04-26 | $3.00 | $372 | -4.3% | -4.3% | -1.4% |
| LIFE | BUY | 2017-04-18 | 2017-04-20 | $3.00 | $8K | -1.6% | +14.5% | +9.7% |
| LIFE | BUY | 2016-12-19 | 2016-12-21 | $2.20 | $152K | +4.3% | +27.7% | +55.3% |
| LIFE | BUY | 2016-04-05 | 2016-04-07 | $3.52 | $9K | +17.5% | -0.6% | -13.5% |
| LIFE | BUY | 2016-04-05 | 2016-04-06 | $3.55 | $9K | +22.8% | -4.6% | -13.5% |
| FATE | BUY | 2013-10-04 | 2013-10-07 | $6.00 | $100K | -21.5% | -1.8% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.